Page 261 - Read Online
P. 261

Parsons et al. J Cancer Metastasis Treat 2018;4:19  I  http://dx.doi.org/10.20517/2394-4722.2018.11                        Page 15 of 23

               This also means that the function of a particular lncRNA using a mouse model of metastasis for instance,
               does not always imply that the mechanism of action of those lncRNAs function similarly in human cells.
               For instance, the use of genetically engineered mouse models (GEMMs) that have a propensity to develop
               metastasis may provide some useful information yet may not provide a complete picture regarding the
               mechanisms by which a specific lncRNA promotes metastasis in human systems. Therefore, additional
               technologies will be required to assess the functionality of metastatic-specific lncRNAs. For instance, the use
               of humanized mouse models, 3D culture systems, and use of conditionally reprogrammed cells from human
               tissue, all will aid investigators in determining the bona fide relevance of functionally conserved lncRNAs.


               In many cases lncRNAs are expressed at lower abundance than cytoplasmic mRNA, thereby making it
               difficult to assess whether lncRNAs are functionally relevant, or present as a result of leaky transcriptional
               activity. As an example, lncRNAs can regulate the processing of nascent transcripts generated from RNA
               polII-based transcription. These lncRNAs may only number a few copies in the cell at any given time yet
               can bind in a 1:1 stoichiometric relationship with the nascent mRNA altering the stability of the newly
               synthesized RNA molecule. Technologies such as global run on sequencing , which is a sensitive and
                                                                                 [187]
               high throughput type of nuclear-run on assay, have been developed to specifically determine the relevant
               abundance of a particular lncRNA binding these nascent transcripts. Additionally, techniques such as high-
               throughput sequencing of RNAs isolated by crosslinking immunoprecipitation (CLIP)  and cross-linking,
                                                                                        [188]
               ligation and sequencing of hybrids (CLASH)  have been utilized to gauge the abundance, enrichment,
                                                      [189]
               and/or composition of composition of ncRNAs within particular RNA-RBP cytoplasmic complexes. As
               sequencing technology develops and the cost to perform these analyses decrease, the utilization of these
               biochemical approaches coupled with these high-throughput sequencing methods will pave the way for new
               discoveries regarding lncRNA function.

               Despite these challenges, it is clear that lncRNAs play a crucial role in driving a metastatic phenotype,
               and in particular regulate the initiating steps of metastasis such as EMT. Given EMT is the process of
               cell fate switching, or reactivation of embryogenic programs that convert epithelia cells to those harboring
               a mesenchymal phenotype, the continued approach of utilizing reductionist-based investigations within
               well-defined model systems will help in elucidating the mechanisms by which individual lncRNAs regulate
               the underlying biology of metastasis. Given the advances in sequencing technology as well as a renewed
               scientific interest in lncRNA biology, the number of publication discussing the role of lncRNAs in metastasis
               will most likely double in the next year. The continued demand for reliable biomarkers of metastasis will also
               fuel research towards the development of prognostic and predictive indicators for patients with high grade
               tumors harboring metastatic dissemination. In conclusion, the lncRNA field is certainly in its infancy, yet
               is considered to be the wild-west of the post-genomic era and has the potential to unlock the key to some of
               the most prevalent challenges associated with treating patients with metastatic disease.


               DECLARATIONS
               Acknowledgments
               We thank Kimberly N. Kelly at BioCT Innovation Commons, as well as Drs. Garret Barr and Ann Yezerski
               Gilmor at King’s  College for providing  the  resources  and  office  space required  for  the  writing of this
               manuscript.

               Authors’ contributions
               Conception and design: Adams BD, Reed IG, Alexander A, Willetts L, Habibian M
               Financial support: Adams BD
               Literature search, manuscript preparation and writing: all authors
               Manuscript editing: Adams BD, Reed IG, Willetts L
               Manuscript review: all authors
   256   257   258   259   260   261   262   263   264   265   266